Bennett Levitan
Overview
Explore the profile of Bennett Levitan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
722
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Newbern E, Wildisen L, Verstraeten R, Willame C, Haynes K, Levitan B, et al.
Pharmacoepidemiol Drug Saf
. 2025 Jan;
34(2):e70099.
PMID: 39887891
Purpose: With the introduction of COVID-19 vaccines, there has been a proliferation of quantitative benefit-risk assessments (qBRAs). Prior work on other types of vaccines has found that published qBRAs have...
2.
Marsh K, Gonzalez Sepulveda J, Berlin C, Levitan B, Boeri M, Groothuis-Oudshoorn C, et al.
Patient
. 2025 Jan;
18(2):101-108.
PMID: 39873903
Using patient preference information (PPI) to incorporate patient voices into the drug development lifecycle can help align therapies with the needs and values of patients. However, several barriers have limited...
3.
Yuan Z, Levitan B, Deng H, Szarek M, Bauersachs R, Berkowitz S, et al.
J Am Heart Assoc
. 2024 Apr;
13(8):e032782.
PMID: 38563380
Background: The VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of...
4.
Bozzi L, Jacobson M, Yost E, Sheahan A, Cafone J, Komatsu Y, et al.
Clin Pharmacol Ther
. 2024 Mar;
115(6):1251-1257.
PMID: 38506485
Recent reports related to in utero exposure of marketed immunosuppressive biologics led to clinical recommendations to delay live vaccinations for infants due to the concern of reduced vaccine effectiveness and/or...
5.
Muhlbacher A, de Bekker-Grob E, Rivero-Arias O, Levitan B, Vass C
Patient
. 2024 Feb;
PMID: 38341385
In health preference research (HPR) studies, data are generated by participants'/subjects' decisions. When developing an HPR study, it is therefore important to have a clear understanding of the components of...
6.
Levitan B, Hadler S, Hurst W, Izurieta H, Smith E, Baker N, et al.
Vaccine
. 2023 Dec;
42(4):972-986.
PMID: 38135642
Vaccine Benefit-Risk (B-R) assessment consists of evaluating the benefits and risks of a vaccine and making a judgment whether the expected key benefits outweigh the potential key risks associated with...
7.
Pinto C, Tervonen T, Jimenez-Moreno C, Levitan B, Soriano Gabarro M, Girman C, et al.
Patient
. 2023 Dec;
17(2):147-159.
PMID: 38085458
Objectives: To understand industry practices and challenges when submitting patient experience data (PED) for regulatory decisions by the US Food and Drug Administration (FDA). Methods: A two-part online survey related...
8.
Okumura K, Inoue H, Yasaka M, Gonzalez J, Hauber A, Levitan B, et al.
J Health Econ Outcomes Res
. 2023 Sep;
2(2):207-220.
PMID: 37663581
Anticoagulants are recommended for stroke prevention in patients with atrial fibrillation (AF), but are associated with an increased risk of bleeding; therefore, physicians face benefit-risk tradeoffs when prescribing anticoagulants to...
9.
Janssens R, Barbier L, Muller M, Cleemput I, Stoeckert I, Whichello C, et al.
Front Pharmacol
. 2023 Sep;
14:1192770.
PMID: 37663265
Patients have unique insights and are (in-)directly affected by each decision taken throughout the life cycle of medicinal products. Patient preference studies (PPS) assess what matters most to patients, how...
10.
Kochhar S, Izurieta H, Chandler R, Hacker A, Chen R, Levitan B
Vaccine
. 2023 Aug;
42(4):969-971.
PMID: 37563049
Benefit-risk assessment (BRA) is critical for decision-making throughout the vaccine life cycle. It requires scientific assessment of evidence to make an informed judgment on whether the vaccine has a favourable...